School of Public Health and Family Medicine, University of Cape Town, Cape Town, South Africa.
Women's Health Research Unit, School of Public Health and Family Medicine, University of Cape Town, Cape Town, South Africa.
BMC Public Health. 2019 Jul 26;19(1):1003. doi: 10.1186/s12889-019-7312-1.
This study explored primary healthcare provider and HIV/contraception expert stakeholder perspectives on South Africa's public sector provision of contraceptive implants to women living with HIV. We investigated the contraceptive service-impact of official advice against provision of implants to women using the HIV antiretroviral drug, efavirenz, issued by the South African National Department of Health (NDoH) in 2014.
Qualitative data was collected in Cape Town in 2017 from primary healthcare contraceptive providers in four clinics that provide implants, as well as from other expert stakeholders selected for expertise in HIV and/or contraception. In-depth interviews and a group discussion explored South Africa's implant introduction and implant provision to women living with HIV. Data was analysed using an inductive thematic analysis approach.
Interviews were conducted with 10 providers and 10 stakeholders. None of the four clinics where the providers worked currently offered the implant to women living with HIV. Stakeholders confirmed that this was consistent with patterns of implant provision at primary healthcare facilities across Cape Town. Factors contributing to providers' decisions to suspend provision of the implant to women living with HIV included: inadequate initial and ongoing provider training; interpretation of NDoH communications about implant use with efavirenz; provider unwillingness to risk harming clients and concerns about professional liability; and other pressures related to provider capacity.
All South African women, including those living with HIV, should have access to the full range of contraceptive options for which they are medically eligible. Changing guidance should be initiated and communicated in consultation with primary-level providers and service beneficiaries. Guidance issued to providers needs to be clear and fully evidence-informed, and its correct interpretation and implementation facilitated and monitored. Guidance should be accompanied by provider training, as well as counselling messages and tools to support providers. Generalized retraining of providers in rights-based, client-centred family planning, and in particular implant provision for women with HIV, is needed. These recommendations accord with the right of women living with HIV to access the highest possible standard of sexual and reproductive healthcare, including informed contraceptive choice and access to the contraceptive implant.
本研究探讨了初级保健提供者和艾滋病毒/避孕专家利益相关者对南非向感染艾滋病毒的妇女提供公共部门避孕植入物的看法。我们调查了官方建议对提供避孕植入物的影响,即南非国家卫生部(NDoH)于 2014 年向使用艾滋病毒抗逆转录病毒药物依非韦伦的妇女发出的反对提供植入物的建议。
2017 年,在开普敦,我们从四家提供植入物的诊所的初级保健避孕提供者以及从在艾滋病毒和/或避孕方面具有专业知识的其他专家利益相关者中收集了定性数据。深入访谈和小组讨论探讨了南非植入物的引入和向感染艾滋病毒的妇女提供植入物的情况。使用归纳主题分析方法分析数据。
对 10 名提供者和 10 名利益相关者进行了访谈。在他们工作的四家诊所中,没有一家诊所目前向感染艾滋病毒的妇女提供植入物。利益相关者证实,这与整个开普敦初级保健设施的植入物提供模式一致。导致提供者决定暂停向感染艾滋病毒的妇女提供植入物的因素包括:提供者最初和持续培训不足;对 NDoH 关于使用依非韦伦的植入物的通信的解释;提供者不愿意冒险伤害客户并担心职业责任;以及与提供者能力相关的其他压力。
所有南非妇女,包括感染艾滋病毒的妇女,都应能够获得她们在医学上有资格获得的所有避孕选择。应在与初级保健提供者和服务受益者协商的基础上启动和传达变更指南。向提供者提供的指导应明确并充分基于证据,并应促进和监测其正确解释和执行。指导应附有提供者培训,以及支持提供者的咨询信息和工具。需要对提供者进行以权利为基础、以客户为中心的计划生育以及特别是向感染艾滋病毒的妇女提供植入物的一般性再培训。这些建议符合感染艾滋病毒的妇女获得最高可能标准的性和生殖保健的权利,包括知情避孕选择和获得避孕植入物的权利。